Intervention

Chemotherapy: Pemetrexed

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting2

Common conditions4

Lead sponsors shown3

Clinical trials

3 shown

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C MutationNCT06946927 · 2025-06-06

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT06667076 · 2024-12-16

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationNCT05609578 · 2022-11-22

ACTIVE_NOT_RECRUITING

Common conditions

Advanced NSCLC1 Carcinoma, Non-Small-Cell Lung1 Metastatic Lung Cancer1 NSCLC (Advanced Non-small Cell Lung Cancer)1

Leading sponsors

Janssen Research & Development, LLC1 Jemincare1 Mirati Therapeutics Inc.1

Trial status mix

RECRUITING2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.